A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Pembrolizumab(biological)

Enrollment

1653 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2026

Study locations (30)

• The University of Alabama at Birmingham ( Site 0010), Birmingham, Alabama, United States
• UC San Diego ( Site 0050), La Jolla, California, United States
• Cedars Sinai Medical Center ( Site 0027), Los Angeles, California, United States
• University of California Irvine ( Site 0029), Orange, California, United States
• UCLA Hematology Oncology Santa Monica ( Site 0048), Santa Monica, California, United States
• Hartford Hospital ( Site 0024), Hartford, Connecticut, United States
• Advent Health Hematology & Oncology ( Site 0003), Orlando, Florida, United States
• University Cancer & Blood Center, LLC ( Site 0057), Athens, Georgia, United States
• Emory University Winship Cancer Institute ( Site 0012), Atlanta, Georgia, United States
• Rush University Medical Center ( Site 0040), Chicago, Illinois, United States
• Parkview Cancer Institute ( Site 0088), Fort Wayne, Indiana, United States
• Norton Cancer Institute - St. Matthews ( Site 0065), Louisville, Kentucky, United States
• Ochsner Medical Center ( Site 0049), New Orleans, Louisiana, United States
• New England Cancer Specialists ( Site 0082), Scarborough, Maine, United States
• Massachusetts General Hospital ( Site 0094), Boston, Massachusetts, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →